StockData
Moderna, Inc. logo

Moderna, Inc.

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)

Close on Nov 2, 2026Market cap $88.16BP/E –Yield –

Moderna Stock-based compensation (SBC) expense — Total by Year

Stock-based compensation (SBC) expense — Total ($M) ($M)

QuarterlyAnnual

Moderna Stock-based compensation (SBC) expense — Total: $483M in FY2025, up 12.6% from a year earlier. That is the highest of the 8 years on record here.

Latest, FY2025
483
Period ended Dec 31, 2025
Change on a year earlier
+12.6%
429 in FY2024
History
8 years
Since FY2018
Sources
6
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-20) ↗

Reported in Form 10-Q / 10-K Note 14 (Stock-Based Compensation).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedStock-based compensation (SBC) expense — Total ($M) ($M)Year on yearSource
FY2025Dec 31, 2025483+12.6%Form 10-K (filed 2026-02-20) ↗
FY2024Dec 31, 2024429+40.7%Form 10-K (filed 2026-02-20) ↗
FY2023Dec 31, 2023305+35.0%Form 10-K (filed 2026-02-20) ↗
FY2022Dec 31, 2022226+59.2%Form 10-K (filed 2025-02-21) ↗
FY2021Dec 31, 2021142+52.7%Form 10-K (filed 2024-02-23) ↗
FY2020Dec 31, 202093+14.8%Form 10-K (filed 2023-02-24) ↗
FY2019Dec 31, 201981+11.6%Form 10-K (filed 2022-02-25) ↗
FY2018Dec 31, 201872.6–Form 10-K (filed 2021-02-26) ↗

Breakdown

What makes up stock-based compensation (SBC) expense — Total

Cite this data

StockData. (2026). Moderna Stock-based compensation (SBC) expense — Total ($M), annual FY2018–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/sbc-total

See every metric in the Moderna KPI table. Data updated Nov 3, 2026.